$0.01 EPS Expected for Harvard Bioscience, Inc. (HBIO)

October 10, 2017 - By Dolores Ford

 $0.01 EPS Expected for Harvard Bioscience, Inc. (HBIO)
Investors sentiment increased to 1.09 in Q2 2017. Its up 0.09, from 1 in 2017Q1. It is positive, as 6 investors sold Harvard Bioscience, Inc. shares while 17 reduced holdings. 8 funds opened positions while 17 raised stakes. 21.19 million shares or 0.54% less from 21.31 million shares in 2017Q1 were reported.
Tfs Cap Ltd reported 0.04% stake. Meristem Llp holds 0.01% or 12,368 shares. Price T Rowe Associates Inc Md has invested 0% of its portfolio in Harvard Bioscience, Inc. (NASDAQ:HBIO). Northern Trust invested in 0% or 86,205 shares. 1,535 are owned by Wells Fargo Mn. Morgan Stanley reported 34,181 shares or 0% of all its holdings. First Light Asset Mgmt Ltd Limited Liability Company holds 3.57 million shares. The Tennessee-based Woodmont Invest Counsel Ltd Llc has invested 0.21% in Harvard Bioscience, Inc. (NASDAQ:HBIO). Bridgeway Cap Mngmt Incorporated stated it has 0.02% of its portfolio in Harvard Bioscience, Inc. (NASDAQ:HBIO). Deutsche State Bank Ag holds 0% of its portfolio in Harvard Bioscience, Inc. (NASDAQ:HBIO) for 8 shares. Blackrock Inc reported 1.55M shares. Sei Co owns 278 shares or 0% of their US portfolio. Jupiter Asset Limited, United Kingdom-based fund reported 335,656 shares. Creative Planning holds 0% in Harvard Bioscience, Inc. (NASDAQ:HBIO) or 810 shares. Panagora Asset Mgmt, Massachusetts-based fund reported 12,464 shares.

Since May 23, 2017, it had 4 buys, and 0 selling transactions for $74,561 activity. 7,712 shares were bought by Green James W, worth $19,666 on Thursday, June 8. Shares for $28,765 were bought by LEWIS EARL R.

Wall Street await Harvard Bioscience, Inc. (NASDAQ:HBIO) to release earnings on October, 26. Analysts forecast earnings per share of $0.01, exactly $0.00 or 0.00 % from 2014’s $0.01 EPS. The expected HBIO’s profit could reach $348,347 giving the stock 93.75 P/E in the case that $0.01 earnings per share is reported. After posting $0.01 EPS for the previous quarter, Harvard Bioscience, Inc.’s analysts now forecast 0.00 % EPS growth. It closed at $3.75 lastly. It is up 25.93% since October 10, 2016 and is downtrending. It has underperformed by 42.63% the S&P500.

Harvard Bioscience, Inc. (NASDAQ:HBIO) Ratings Coverage

Among 2 analysts covering Harvard Bioscience Inc (NASDAQ:HBIO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Harvard Bioscience Inc had 2 analyst reports since July 28, 2015 according to SRatingsIntel. As per Thursday, November 17, the company rating was initiated by Singular Research. The stock of Harvard Bioscience, Inc. (NASDAQ:HBIO) has “Buy” rating given on Tuesday, July 28 by Benchmark.

Harvard Bioscience, Inc. is a developer, maker and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The company has market cap of $130.63 million. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. It currently has negative earnings. The Company’s product range is organized into three commercial product families: Cell and Animal Physiology , Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA).

More important recent Harvard Bioscience, Inc. (NASDAQ:HBIO) news were published by: Seekingalpha.com which released: “Harvard Bioscience’s (HBIO) CEO Jeffrey Duchemin on Q1 2017 Results - Earnings …” on April 27, 2017, also Seekingalpha.com published article titled: “Harvard Bioscience’s (HBIO) CEO Jeffrey Duchemin on Q2 2017 Results - Earnings …”, Bizjournals.com published: “​How Harvard Bioscience deals with the pros and cons of its own name” on July 12, 2016. More interesting news about Harvard Bioscience, Inc. (NASDAQ:HBIO) was released by: Seekingalpha.com and their article: “Harvard Bioscience’s Recent Acquisitions Make A Difference, Initiate With Buy …” with publication date: December 13, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com